Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 105 clinical trials
None
Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's Lymphomas

This phase II trial studies how well obinutuzumab and ibrutinib work as front line therapy in treating patients with indolent non-Hodgkin's lymphoma. Monoclonal antibodies, such as obinutuzumab

ct scan
follicular lymphoma
monoclonal antibodies
cytopenia
marginal zone lymphoma
  • 62 views
  • 23 Mar, 2021
  • 1 location
None
Daratumumab and Ibrutinib in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia

This phase Ib trials studies the side effects of daratumumab and ibrutinib and how well they work in treating patients with symptomatic chronic lymphocytic leukemia. Monoclonal antibodies, such

night sweats
cancer
fever
corticosteroids
thrombocytopenia
  • 45 views
  • 18 Sep, 2021
  • 1 location
None
Venetoclax Ibrutinib Prednisone Obinutuzumab and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma

learn how certain drugs work together to treat B-cell lymphomas. The drugs are venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide (ViPOR). Objective

diffuse large b-cell lymphoma
revlimid
b-cell lymphoma
cancer
white blood cells
  • 71 views
  • 21 Nov, 2021
  • 1 location
None
Ibrutinib in Treating Participants With Untreated High Risk Smoldering Mantle Cell Lymphoma

This phase II trial studies how well ibrutinib works in treating participants with untreated high risk smoldering mental cell lymphoma. Ibrutinib may stop the growth of tumor cells by blocking

cyclin d1
remission
cytopenia
tumor cells
cancer
  • 0 views
  • 25 Jan, 2021
None
Ibrutinib Bortezomib and Rituximab-CHOP for the Treatment of Elderly Patients With CD20+ DLBCL IPI 2

The ImbruVeRCHOP-Trials is an Investigator-initiated, single-arm, multi-center, prospective, open phase I/II trial to evaluate the efficacy and feasibility of Ibrutinib and Bortezomib in the

ct scan
vincristine
renal function
b-cell lymphoma
rituximab
  • 4 views
  • 28 Jan, 2021
  • 2 locations
None
Bruton's Tyrosine Kinase Inhibitor Ibrutinib as Maintenance Treatment in Elderly Patients With Primary CNS Lymphoma

one more chemotherapy agent). Patients with MRI documented response CR or PR will enter the study protocol maintenance phase which will include continous treatment with Ibrutinib 560 mg day

diffuse large b-cell lymphoma
renal function
maintenance treatment
rituximab
methotrexate
  • 0 views
  • 29 Mar, 2021
  • 1 location
None
Ibrutinib Fludarabine Phosphate Cyclophosphamide and Obinutuzumab in Treating Patients With Chronic Lymphocytic Leukemia

This phase II trial studies how well ibrutinib, fludarabine phosphate, cyclophosphamide, and obinutuzumab work in treating patients with chronic lymphocytic leukemia. Ibrutinib may stop the

monoclonal protein
platelet count
monoclonal antibodies
cyclophosphamide
beta human chorionic gonadotrophin
  • 0 views
  • 29 Jul, 2021
  • 1 location
None
Ibrutinib and Blinatumomab in Treating Patients With Relapsed or Refractory B Acute Lymphoblastic Leukemia

This phase II trial studies how well ibrutinib and blinatumomab work in treating patients with B acute lymphoblastic leukemia that has come back or is not responding to treatment. Ibrutinib may

monoclonal protein
monoclonal antibodies
blinatumomab
hysterectomy
lymphoblasts
  • 2 views
  • 20 Oct, 2021
  • 1 location
None
Trial of Ibrutinib Plus Trastuzumab in HER2-amplified Metastatic Breast Cancer

This is a Phase I/II, open-label dose-escalation study designed to evaluate the maximum tolerated dose (MTD) and dose-limiting side effects of ibrutinib (560 or 840 or 420 mg daily oral dose

erbb2
ejection fraction
HER2
muga scan
cancer chemotherapy
  • 36 views
  • 10 Mar, 2021
  • 1 location
None
Ibrutinib in Preventing Acute Leukemia in Patients After Reduced-Intensity Conditioning and Stem Cell Transplant

This phase II trial studies how well ibrutinib works in preventing acute leukemia in patients after reduced-intensity conditioning and stem cell transplant. Ibrutinib may stop the growth of

tacrolimus
graft versus host disease
methotrexate
acute biphenotypic leukemia
myeloablative conditioning
  • 54 views
  • 24 Jan, 2021
  • 1 location